Oncovita Granted Orphan Drug Designation For MVdeltaC in Mesothelioma by the European Commission

On November 9, 2026 Oncovita, a French biotechnology company specialized in therapeutic and prophylactic vaccines, reported that the European Commission has granted orphan medicinal product designation to its lead investigational candidate, MVdeltaC, for the treatment of mesothelioma.
The decision, dated October 19, 2026, follows a positive opinion adopted on September 10, 2026, by the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP). It complements the U.S. Food and Drug Administration (FDA) orphan drug designation for MVdeltaC in pleural mesothelioma, announced in June 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A significant European regulatory milestone

European orphan designation involves an assessment of both the rare-disease criteria and the therapeutic context. Where satisfactory treatments are already authorised, sponsors must provide evidence supporting an assumption that their candidate could offer significant benefit to patients compared with existing methods.

"The European designation is an important milestone for MVdeltaC, particularly because the EU framework requires a substantiated rationale for potential significant benefit when treatments already exist," said Stéphane Altaba, CEO of Oncovita. "Together with the FDA designation obtained in 2025, it provides further encouragement for our development programme in mesothelioma. Our priority is now to advance our drug candidate into clinical development in late 2027 ".

A new immunotherapeutic approach for a challenging cancer

Mesothelioma is a rare and aggressive cancer. Its pleural form affects the membrane surrounding the lungs and is commonly associated with past asbestos exposure. Despite advances in treatment, substantial unmet needs remain, particularly for a majority of patients whose disease progresses with currently available therapies.
MVdeltaC is an investigational immuno-oncolytic therapy developed using Oncovita’s proprietary Measovir platform. It is based on the attenuated Schwarz strain of the measles vaccine virus, genetically modified to inactivate the viral C virulence factor.
The candidate is designed to combine direct lysis of tumour cells with activation of an anti-tumour immune response. Preclinical studies presented at the European Association for Cancer Research congress in June 2026 reported immunogenic tumour cell death, anti-tumour activity and immune memory in several experimental models of cancer, including mesothelioma models.

"Patients with pleural mesothelioma urgently need additional treatment options, particularly when their disease progresses despite existing therapies," said Professor Arnaud Scherpereel, a specialist in pneumology and thoracic oncology at Lille University Hospital. "MVdeltaC is a promising therapeutic approach, combining direct tumour cell killing with the potential to stimulate a broader anti-tumour immune response.The preclinical findings are encouraging and strengthen the rationale for bringing this innovative approach into clinical development. I believe MVdeltaC deserves to be investigated clinically for its potential to provide a meaningful new treatment option for patients with mesothelioma."

Clinical development planned for late 2027

Oncovita is preparing the transition of MVdeltaC into clinical development, including GMP/clinical-grade manufacturing. The company plans to initiate its first clinical trial in late 2027, subject to the required regulatory and ethics approvals.
The European and U.S. orphan designations provide access to incentives intended to support the development of treatments for rare diseases. In the EU, these include protocol assistance, potential reductions in regulatory fees and eligibility for ten years of market exclusivity following marketing authorisation, provided the applicable conditions are met.

(Press release, Oncovita, NOV 9, 2026, View Source [SID1234674520])

Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study

On November 9, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, reported that a patient with advanced liver cancer who participated in its completed Phase II study of Namodenoson has reached ten years of overall survival. The patient, whose complete response was previously reported by the Company, remains cancer-free and in good health.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This decade-long survival marks an exceptional individual outcome in advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. Following the Company’s announcement of nine-year survival in November 2025, the patient’s continued well-being adds another year to this remarkable clinical story.

"Behind this ten-year milestone is a woman who continues to live well a decade after participating in our study with advanced liver cancer. For patients, families, and those of us working to develop new treatments, this is a deeply meaningful achievement," said Prof. Pnina Fishman, Chairperson and Chief Scientific Officer of Can-Fite. "Her exceptional outcome strengthens our commitment to advancing Namodenoson and evaluating its potential to provide durable clinical benefit for patients with liver cancer."

Namodenoson is currently being evaluated in Can-Fite’s ongoing randomized, double-blind, placebo-controlled pivotal Phase III study in patients with advanced HCC and underlying Child-Pugh B7 cirrhosis. As announced on September 2, 2026, overall survival across the pooled, blinded study population appeared longer than anticipated based on the study’s design assumptions, prompting the Company to evaluate earlier timing for the planned interim analysis. The study remains blinded, and the survival observation includes both Namodenoson- and placebo-treated patients; treatment-specific efficacy will be assessed through the planned analysis.

About Namodenoson

Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is currently being evaluated in a pivotal Phase 3 trial for advanced liver cancer, concluded successfully a Phase 2a study in pancreatic cancer and is enrolling patients in a Phase 2b trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential expression may be one of the important factors that accounts for the excellent safety profile of the drug.

(Press release, Can-Fite BioPharma, NOV 9, 2026, View Source [SID1234674465])

Nanobiotix to Participate in Investor Conferences in November

On November 9, 2026 NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, reported that Company management will participate in the following investor conferences in November:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference in London
Date: Monday, November 16, 2026
Presentation Time: 8:30am ET / 1:30pm GMT
Location: London (UK)
Presenters: Laurent Levy, Chief Executive Officer and Arnd Christ, Chief Financial Officer

UBS Global Biopharma Conference
Date: Tuesday, November 17, 2026
Location: London (UK)

(Press release, Nanobiotix, NOV 9, 2026, View Source [SID1234674481])

PharmaLogic to Acquire Lantheus’ CDMO Business and Springfield, New Jersey Manufacturing Facility

On November 9, 2026 PharmaLogic Holdings Corp. ("PharmaLogic" or the "Company"), the only independent contract development and manufacturing organization (CDMO) of scale dedicated exclusively to radiopharmaceuticals, reported a definitive agreement to acquire the CDMO business and Springfield, New Jersey manufacturing facility from Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH). The financial terms of the transaction were not disclosed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Springfield facility is a state-of-the-art radiopharmaceutical manufacturing site with a proven track record in theranostic manufacturing, research and clinical development. Its highly skilled team will join Agilera, PharmaLogic’s therapeutic CDMO franchise, upon completion of the transaction. The transaction also includes a long-term supply agreement under which Agilera will manufacture lutetium Lu 177 dotatate for Lantheus.

The acquisition expands PharmaLogic’s capacity to manufacture radiopharmaceutical therapeutics in the U.S. Agilera brings more than 15 years of experience supporting the development and commercial launch of radioligand therapies (RLTs) and currently supplies an alpha therapy to more than 30 countries. With the Springfield facility, PharmaLogic becomes the first therapeutic CDMO to offer a transatlantic platform, giving partners an end-to-end solution for RLTs, from early clinical development through commercial launch and global supply.

"This acquisition strengthens Agilera’s unique capabilities in radioligand therapies and expands our capacity in the U.S.," said Etienne Montagut, President and Chief Executive Officer of PharmaLogic. "We are proud to welcome the talented Springfield team, who will help us scale our operations to meet growing demand from our partners and the patients they serve."

"We have a long-standing relationship with PharmaLogic, which has been an important manufacturing partner for our PET products," said Mary Anne Heino, Executive Chairperson and Chief Executive Officer of Lantheus. "With its proven radiopharmaceutical expertise and manufacturing capabilities, PharmaLogic is the right long-term owner for the CDMO business and Springfield facility, with the capabilities to build on this foundation while supporting reliable supply of our newly approved radiotherapeutic for patients and healthcare providers."

The transaction is subject to applicable regulatory review and the satisfaction of other customary closing conditions. The parties will continue to operate independently until the closing.

Advisors

Leerink Partners served as financial advisor to the Company, and Goodwin Procter LLP served as legal advisor.

Solomon Partners Securities LLC served as financial advisor to Lantheus, and Covington & Burling LLP served as legal advisor.

(Press release, Lantheus, NOV 9, 2026, View Source [SID1234674505])

BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC

On Nvoember 9, 2026 BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, reported the outcome of its End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) regarding BH-30643 for the treatment of patients with advanced or metastatic epidermal growth factor receptor (EGFR) C797S-positive non-small cell lung cancer (NSCLC). BH-30643 is an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective, OMNI-EGFR inhibitor designed to overcome the limitations of currently approved EGFR inhibitors for the treatment of EGFR-mutant NSCLC.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BlossomHill plans to advance BH-30643 into SOLARA-2, the Phase 2 portion of the SOLARA trial, following alignment with FDA on a recommended Phase 2 dose of 50 mg twice daily. SOLARA-2 is the global, open-label, single-arm Phase 2 portion of the SOLARA trial, intended to generate data that could potentially support an accelerated approval application in patients with EGFR C797S-positive NSCLC, a population for which there are currently no approved oral targeted therapies. SOLARA-2 is designed to evaluate both chemotherapy-naive and chemotherapy-pretreated patients following treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI). The trial will leverage the current global footprint of the SOLARA trial, with the first patient anticipated to be dosed in the first quarter of 2027. BH-30643 previously received FDA Fast Track designation for EGFR C797S-positive NSCLC.

"We are pleased with the outcome of our End-of-Phase 1 meeting with FDA and are confident in our development strategy for BH-30643 in EGFR C797S-positive NSCLC. Our planned Phase 2 trial, designed with registrational intent, builds on the encouraging clinical activity observed in SOLARA, where BH-30643 has demonstrated promising anti-tumor activity in NSCLC patients with EGFR C797S-positive resistance, including those with and without concurrent T790M mutation and brain metastasis, and those who have received multiple prior therapies," said J. Jean Cui, Ph.D., Founder and Chief Executive Officer of BlossomHill Therapeutics. "The selection of 50 mg twice daily as our recommended Phase 2 dose, together with the clinical experience we have observed to date, provides strong support for advancing the program. By evaluating BH-30643 in both chemotherapy-naive and chemotherapy-pretreated patients, we aim to further characterize its potential to address this important resistance mechanism and generate the evidence needed to support a potential accelerated approval."

Preliminary data from SOLARA were presented in 2026 at both the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) and World Conference on Lung Cancer (WCLC). The company expects to share additional updates from SOLARA at medical meetings in 2027, including updates on C797S durability and TKI-naive durability, as well as initial data from the chemotherapy-combination cohort.

SOLARA-2 Trial
SOLARA-2 is the pivotal single-arm Phase 2 portion of the SOLARA trial, designed with registrational intent to evaluate BH-30643 in approximately 150 patients with locally advanced or metastatic EGFR C797S-positive NSCLC who have previously received a third-generation EGFR TKI. The open-label study will include two sub-cohorts of approximately 75 patients each: chemotherapy-naive patients and chemotherapy-pretreated patients. All patients will receive BH-30643 at the recommended Phase 2 dose of 50 mg twice daily. The primary endpoint will be objective response rate (ORR), as assessed by blinded independent central review (BICR), with additional endpoints including duration of response (DOR), progression-free survival (PFS), overall survival (OS), intracranial ORR and safety. For additional information on SOLARA, including a list of study sites and how to enroll, please visit clinicaltrials.gov (NCT06706076).

About BH-30643
BH-30643 is an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective, OMNI-EGFR inhibitor for the treatment of EGFR-mutant NSCLC. BH-30643 was designed to overcome the limitations of currently approved EGFR inhibitors, which were discovered over a decade ago without the current, modern understanding of the structure and protein dynamics of mutant EGFRs. In preclinical studies, BH-30643 demonstrated potent inhibitory activity across diverse EGFR mutation categories — classical mutations, on-target resistance mutations such as C797S with or without T790M, atypical mutations and exon 20 insertions — while maintaining marked selectivity over wild-type EGFR. BH-30643 has received Fast Track designation and is being evaluated in SOLARA, a global Phase 1, first-in-human clinical trial with ongoing dose expansion cohorts enrolling in both TKI-pretreated and TKI-naive settings, including a C797S resistance cohort. SOLARA-2, a global Phase 2 pivotal study in C797S-Positive NSCLC is scheduled to dose the first patient in the first quarter of 2027. For additional information on SOLARA, including a list of study sites and how to enroll, please visit clinicaltrials.gov (NCT06706076).

(Press release, BlossomHill Therapeutics, NOV 9, 2026, View Source [SID1234674521])